查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957321

生物製藥發酵市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

Biopharmaceutical Fermentation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物製藥發酵市場預計將從 2025 年的 251.1 億美元成長到 2031 年的 409.9 億美元，複合年成長率為 8.51%。

在這個領域，生物反應器利用細菌、酵母和哺乳動物細胞等生物系統生產單株抗體和疫苗等治療藥物。推動該領域發展的主要因素是全球慢性病盛行率的上升以及對生物治療方法日益成長的需求。此外，重磅藥物專利到期加速了生物相似藥的研發，從而持續推高了生產能力。歐洲製藥工業協會聯合會（EFPIA）估計，到2024年，歐洲製藥業在研發方面的投資將達到550億歐元，這凸顯了這些生產需求所獲得的巨額資金支持。

市場概覽
預測期 2027-2031
市場規模：2025年 251.1億美元
市場規模：2031年 409.9億美元
複合年成長率：2026-2031年 8.51%
成長最快的細分市場 生物製藥業
最大的市場 北美洲

市場成長的主要障礙在於建造和驗證符合cGMP標準的設施所需的大量資本支出。將發酵製程從實驗室規模放大到商業化生產的技術難題也構成了重要的進入門檻。這種財務和技術負擔常常限制了小規模生產商快速擴大產能的能力，可能導致供應鏈瓶頸，並阻礙新療法進入商業市場的速度。

市場促進因素

生物製藥研發投入的增加是發酵市場發展的重要驅動力。隨著企業積極研發新型生物製藥，這筆不斷成長的投資支持了對單株抗體和重組蛋白等複雜分子的研究，因為先進的發酵技術對於這些分子的開發和商業化至關重要。資金的增加使製造商能夠最佳化上游工程程式參數並提高產量，從而確保有前景的候選療法能夠順利地從實驗室規模過渡到工業生物反應器。根據美國製藥製造商協會 (PhRMA) 於 2024 年 4 月發布的《2024 年 PhRMA 年度會員調查》，會員公司在 2023 年的研發投入高達 1035 億美元，這表明大量資金正湧入，支持發酵衍生療法的創新研發。

將生產外包給合約研發生產機構（CDMO）的趨勢日益成長，這透過緩解創新者面臨的產能限制，進一步擴大了市場規模。隨著符合cGMP規範的發酵技術標準日益嚴格，製藥研發公司正利用CDMO的專業基礎設施來降低資本風險並縮短產品上市時間。三星生物製劑在2024年1月公佈的2023年第四季及全年財務業績中，其合併年銷售額達到3.69兆韓元，凸顯了市場對外包服務的強勁需求。為了滿足全球對生物製藥日益成長的需求，主要企業也努力提升自身的生產能力。例如，諾和諾德承諾在2024年投資41億美元，在北卡羅來納州新建一座生產設施，旨在提高注射劑的產量。

市場挑戰

建立和驗證符合cGMP規範的設施需要巨額資本投入，這是全球生物製藥發酵市場面臨的主要障礙。這筆高額資金門檻主要限制了市場准入，只有資金雄厚的大型製藥公司才能進入，實際上將無力承擔巨額前期投資的中小型製造商和Start-Ups排除在外。因此，生產能力高度集中，供應鏈的韌性和柔軟性受到影響。此外，發酵製程從實驗室規模放大到商業規模的技術難題也加劇了這個問題。製程偏差和驗證失敗可能造成巨大損失，並可能延遲關鍵治療藥物的上市。

這些經濟限制因素直接阻礙了產能擴張以滿足日益成長的全球需求。將一種藥物推向市場的相關成本，包括實施嚴格的生產控制，清楚地表明了產品成功所需的巨額投資。根據國際藥品製造商協會聯合會（IFPMA）估計，到2024年，開發一種新藥的平均成本將達到26億美元。如此龐大的成本結構迫使企業在為新設施分配資金時格外謹慎，導致基礎設施瓶頸，阻礙了發酵市場的進一步擴張。

市場趨勢

隨著相關人員越來越重視環境管理，向永續和環保生物製造方法的轉變正在改變商業運作。製造商正在逐步淘汰再生能源來源，並最佳化用水，以實現供應鏈脫碳並達成雄心勃勃的淨零排放目標。這項策略轉變旨在降低長期營運成本，同時滿足工業排放的監管要求。例如，在2025年12月發表於《醫療保健數字》（Healthcare Digital）的一篇題為“安進如何將拯救生命的生物技術與永續性相結合”的報導中，安進宣布將於2025年投資9億美元擴建其位於俄亥俄州的工廠，這將是該公司首個全電動製造地，以支持其碳中和目標。

同時，人工智慧數位雙胞胎技術的整合正在革新市場上的規模化生產和生命週期管理。借助先進的演算法，製造商可以即時模擬發酵過程，預測影響效力的各種變量，而無需進行大量的物理實驗。這種數位化變革有助於預測性維護，減少批次失敗，並大幅加快研發進度。為了支持這項技術進步，賽諾菲在2025年9月發布的新聞稿中宣布增加對技術支援的投入，以推動其人工智慧驅動的生物製藥策略。新聞稿題為「賽諾菲向賽諾菲創投追加投資6.25億美元，加速生物技術和數位健康領域的創新投資」。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球生物製藥發酵市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（上游工程產品、下游製程產品）
    • 依應用領域（抗生素、重組蛋白等）
    • 按最終用戶分類（生物製藥產業、受託研究機構、學術研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物製藥發酵市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物製藥發酵市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物製藥發酵市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物製藥發酵市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物製藥發酵市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物製藥發酵市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • Eppendorf SE
  • Thermo Fisher Scientific Inc.
  • c-LEcta GmbH
  • Sartorius AG
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Nova Biomedical Corporation
  • Concord Biotech Limited
  • Solaris Biotechnolgy Srl

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18837

The Global Biopharmaceutical Fermentation Market is projected to expand from USD 25.11 Billion in 2025 to USD 40.99 Billion by 2031, reflecting a CAGR of 8.51%. This sector utilizes biological systems, including bacteria, yeast, or mammalian cells, within bioreactors to produce therapeutic agents such as monoclonal antibodies and vaccines. Growth is primarily fuelled by the increasing prevalence of chronic diseases worldwide and the growing necessity for biologic treatments. Additionally, the patent expiration of key blockbuster medications is hastening the development of biosimilars, creating a continuous requirement for enhanced manufacturing capabilities. Highlighting the substantial financial backing for these production needs, the European Federation of Pharmaceutical Industries and Associations estimated that the industry invested 55,000 million Euros in research and development across Europe in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 25.11 Billion
Market Size 2031USD 40.99 Billion
CAGR 2026-20318.51%
Fastest Growing SegmentBiopharmaceutical Industries
Largest MarketNorth America

A major obstacle hindering market growth is the immense capital expenditure needed to build and validate facilities that comply with cGMP standards. The technical difficulties involved in scaling fermentation processes from laboratory settings to commercial manufacturing establish significant entry barriers. This financial and technical strain frequently restricts smaller manufacturers' ability to rapidly increase capacity, which can lead to supply chain bottlenecks and impede the pace at which new therapeutic products reach the commercial market.

Market Driver

Increasing R&D spending in biopharmaceutical discovery is a fundamental driver of the fermentation market, as companies aggressively seek to develop novel biologics. This rise in financial investment supports the investigation of complex molecules, such as monoclonal antibodies and recombinant proteins, which depend heavily on sophisticated fermentation methods for development and commercialization. Enhanced funding enables manufacturers to refine upstream bioprocessing parameters and boost yields, ensuring that promising therapeutic candidates can successfully transition from laboratory scales to industrial bioreactors. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) '2024 PhRMA Annual Membership Survey' released in April 2024, member companies invested $103.5 billion in research and development during 2023, representing a massive capital influx that sustains the innovation pipeline for fermentation-derived therapeutics.

The growing trend of outsourcing production to Contract Development and Manufacturing Organizations (CDMOs) is further broadening market scope by relieving capacity limitations for innovators. As the technical standards for cGMP-compliant fermentation tighten, pharmaceutical developers are utilizing the specialized infrastructure of CDMOs to reduce capital risks and hasten time-to-market. Samsung Biologics highlighted this robust demand for outsourced services in its 'Fourth Quarter and Annual 2023 Financial Results' from January 2024, reporting a consolidated annual revenue of KRW 3.69 trillion. To satisfy the rising global demand for biologic supplies, major industry players are also strengthening their internal capacities; for instance, Novo Nordisk committed to a $4.1 billion investment in 2024 to build a new manufacturing facility in North Carolina, specifically aimed at increasing the production of injectable treatments.

Market Challenge

The substantial capital expenditure necessary to establish and validate cGMP-compliant facilities represents a major hurdle for the Global Biopharmaceutical Fermentation Market. This high financial threshold restricts market entry largely to major, well-funded pharmaceutical companies, effectively excluding smaller manufacturers and startups that cannot afford such significant upfront investments. As a result, manufacturing capacity remains concentrated, diminishing the resilience and flexibility of the supply chain. The technical difficulties associated with scaling fermentation processes from lab benchmarks to commercial volumes further intensify this issue, as the costs related to process deviations or validation failures can be prohibitive, potentially delaying the rollout of critical therapeutics.

These economic constraints directly limit the rate at which the industry can broaden its production capabilities to satisfy rising global demand. The sheer scale of investment required for successful product launches is underscored by the expenses involved in bringing a drug to market, which includes implementing strict manufacturing controls. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the average cost to develop a new medicine was estimated at USD 2.6 billion in 2024. This massive cost structure compels companies to allocate capital for new facilities with extreme caution, resulting in infrastructure bottlenecks that impede the broader expansion of the fermentation market.

Market Trends

The move towards Sustainable and Green Bio-Manufacturing Practices is transforming operations as stakeholders place a higher priority on environmental stewardship. Manufacturers are progressively adopting renewable energy sources and optimizing water usage to decarbonize supply chains and achieve ambitious net-zero goals. This strategic shift is designed to lower long-term operational expenses while satisfying regulatory demands concerning industrial emissions. For instance, according to a December 2025 article by Healthcare Digital titled 'How Amgen Combines Life-Saving Biotech & Sustainability', Amgen announced a US$900 million expansion for its Ohio facility in 2025, which is intended to be its first fully electric biomanufacturing site in support of carbon neutrality objectives.

Simultaneously, the integration of AI and Digital Twins for Process Optimization is revolutionizing scale-up and lifecycle management within the market. By utilizing advanced algorithms, manufacturers are able to simulate fermentation processes in real-time, allowing them to predict variables impacting titer without the need for extensive physical experimentation. This digital evolution facilitates predictive maintenance, decreases batch failures, and notably hastens development schedules. To back this technological advancement, Sanofi announced in a September 2025 press release titled 'Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation' that it has increased funding to support technologies that drive its AI-powered biopharmaceutical strategy.

Key Market Players

  • Agilent Technologies, Inc.
  • Eppendorf SE
  • Thermo Fisher Scientific Inc.
  • c-LEcta GmbH
  • Sartorius AG
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Nova Biomedical Corporation
  • Concord Biotech Limited
  • Solaris Biotechnolgy Srl

Report Scope

In this report, the Global Biopharmaceutical Fermentation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Fermentation Market, By Product Type

  • Upstream Products
  • Downstream Products

Biopharmaceutical Fermentation Market, By Application

  • Antibiotics
  • Recombinant Proteins
  • Others

Biopharmaceutical Fermentation Market, By End User

  • Biopharmaceutical Industries
  • Contract Research Organization
  • Academic Research Institutes
  • Others

Biopharmaceutical Fermentation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Fermentation Market.

Available Customizations:

Global Biopharmaceutical Fermentation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Fermentation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Upstream Products, Downstream Products)
    • 5.2.2. By Application (Antibiotics, Recombinant Proteins, Others)
    • 5.2.3. By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Biopharmaceutical Fermentation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biopharmaceutical Fermentation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Biopharmaceutical Fermentation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Biopharmaceutical Fermentation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Biopharmaceutical Fermentation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biopharmaceutical Fermentation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Biopharmaceutical Fermentation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Biopharmaceutical Fermentation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Biopharmaceutical Fermentation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Biopharmaceutical Fermentation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Biopharmaceutical Fermentation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biopharmaceutical Fermentation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Biopharmaceutical Fermentation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Biopharmaceutical Fermentation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Biopharmaceutical Fermentation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Biopharmaceutical Fermentation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Biopharmaceutical Fermentation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biopharmaceutical Fermentation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Biopharmaceutical Fermentation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Biopharmaceutical Fermentation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Biopharmaceutical Fermentation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biopharmaceutical Fermentation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Biopharmaceutical Fermentation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Biopharmaceutical Fermentation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biopharmaceutical Fermentation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eppendorf SE
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. c-LEcta GmbH
  • 15.5. Sartorius AG
  • 15.6. Danaher Corporation
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. Nova Biomedical Corporation
  • 15.9. Concord Biotech Limited
  • 15.10. Solaris Biotechnolgy Srl

16. Strategic Recommendations

17. About Us & Disclaimer